Business Wire

BONA

15.1.2024 08:05:25 CET | Business Wire | Press release

Share
Announcing the Launch of Bona Mega EVO™

Bona, a global, sustainably driven company that supplies products for installing, renovating, maintaining, and restoring premium floors, is announcing the launch of its new lacquer, Bona Mega EVO™. This next generation lacquer offers a new state-of-the-art crosslinking technology that activates when applied. The unique, non-yellowing formula delivers faster curing with excellent resistance to scratches, wear, and chemicals. With VOC levels below 3%, the lacquer contributes to healthier working conditions with a lower impact on indoor air quality.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240114100435/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Announcing Bona Mega EVO™ a next generation lacquer that offers new state-of-the-art crosslinking technology that activates when applied. The unique, non-yellowing formula delivers faster curing with excellent resistance to scratches, wear, and chemicals. With VOC levels below 3%, Bona Mega EVO contributes to healthier working conditions with a lower impact on indoor air quality. (Photo: Business Wire)

Bona Mega EVO™ is the next evolution of Bona Mega, which was first introduced in 1996 and offered an industry-first oxygen crosslinking technology and, at the time, was considered a top choice among flooring contractors for use as a one-component topcoat for wood floors in environments requiring medium to light commercial wear resistance. Bona Mega EVO™ is the next generation that incorporates a completely new and significantly faster technology that is unique to Bona. The self crosslinking occurs entirely within the lacquer without the use of any external components, making it a next generation coating.

“When it comes to performance, Bona Mega EVO™ is an advancement in every way. With the new self crosslinking technology, we have merged the top features from Bona Mega and Bona Mega ONE to create an exceptional product. It stands out from the competition due to its consistently high level of performance. Bona Mega EVO™ is the next step for coating medium- to light-commercial areas and domestic wood floors,” said Thomas Hallberg, Director Product Management Professional EMEA/APAC, Bona AB

Bona Mega EVO’s new self crosslinking technology provides a topcoat that dries quickly, remains clear over time, offers excellent sanding ability, and has VOC levels below 3%. It has high filling abilities, low odour, and excellent scratch, wear, and chemical resistance. With Bona Mega EVO’s fast-drying and quick cure time, the floor can be in use more quickly when compared to other one-component lacquers. This also means that the next topcoat layer can be applied much sooner than with traditional polymer technology.

Bona Mega EVO™ guarantees a uniform colouring of the wood floor even without the use of a primer making it possible to use just one product during the whole process. It has a non-yellowing formula with minimal odour during the application process and dissipates rapidly afterwards.

With VOC levels below 3%, Bona Mega EVO™ fulfills the EMICODE® EC1PLUS certification. Bona continues its work to phase out PFAS, of which Bona Mega EVO is no exception, promoting a safer environment.

About Bona

Bona is a family-owned, sustainably driven company that supplies products for installing, renovating, maintaining and restoring premium floors. Founded in 1919, Bona was the first in the industry to offer a full system of waterborne hardwood floor finishing and floor care products. Today, Bona offers products for most premium floor surfaces including wood, tile, vinyl, resilient, rubber and laminate. The head office is in Malmö, Sweden, and the company is represented globally across 90 countries through 16 subsidiaries, 70 distributors, 4 production sites and over 600 employees. For more visit www.bona.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240114100435/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye